ScholarLens Back to search
1989•Drug and Therapeutics BulletinRequires access

▾Cefuroxime axetil: a new oral cephalosporin

Author information unavailable

Open publisher page 1 citations

Abstract

Parenteral cefuroxime (Zinacef - Glaxo) has been available for over 10 years. It is now available for oral administration as cefuroxime axetil (▾Zinnat). Cefuroxime is stable to many β-lactamases and is active against many Gram-positive and Gram-negative organisms. Like most other cephalosporins, it is not active against Streptococcus faecalis, Pseudomonas spp or Bacteroides spp. We compared its activity with other cephalosporins in a previous issue.1 It is being promoted especially for use in chest and urinary tract infections.

About this research paper

What this paper is about

Parenteral cefuroxime (Zinacef - Glaxo) has been available for over 10 years. It is now available for oral administration as cefuroxime axetil (▾Zinnat). Cefuroxime is stable to many β-lactamases and is active against many Gram-positive and Gram-negative organisms. Like most other cephalosporins, it is not active against Streptococcus faecalis, Pseudomonas spp or Bacteroides spp. We compared its activity with other cephalosporins in a previous issue.1 It is being promoted especially for use in chest and urinary tract infections.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Parenteral cefuroxime (Zinacef - Glaxo) has been available for over 10 years. It is now available for oral administration as cefuroxime axetil (▾Zinnat). Cefuroxime is stable to many β-lactamases and is active against many Gram-positive and Gram-negative organisms. Like most other cephalosporins, it is not active against Streptococcus faecalis, Pseudomonas spp or Bacteroides spp. We compared its activity with other cephalosporins in a previous issue.1 It is being promoted especially for use in chest and urinary tract infections.

Key concepts: Cefuroxime, Cephalosporin, Medicine, Bacteroides, Microbiology, Antibiotics, Biology, Bacteria

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
▾Cefuroxime axetil: a new oral cephalosporin — Research Paper | ScholarLens